P-209: Evaluation of Common Risk Factors in Patients with Endometrial Hyperplasia
نویسندگان
چکیده مقاله:
Background: One of the most common abnormality in female genital system, especially in premenopausal period, is abnormal uterine bleeding caused by endometrial hyperplasia. Prevalence of endometrial hyperplasia is 5-20% with different risk factors such as hypertension, diabetes mellitus (DM), multiparity, nuliparity, advanced age, and using estrogen consumption. This study try to determine risk factors in endometrial hyperplasia. Materials and Methods: This case-control study has been done on 200 patients with endometrial hyperplasia who refer to Shahid Sadoughi and Mother Hospital with simple sampling and were compared to 200 control with similar conditions. Questionnaires were filled according to pathological records of 200 patients, which included age, parity, history of hypertension and DM. Finally data were analyzed by SPSS version 14 and ANOVA and Chi-square statistical test. Results: The average age of cases was 47.88. Frequency distribution of hypertension, DM' nulliparity was significantly higher in cases more than controls. Cases had more pregnancy than control. Conclusion: Determining the endometrial hyperplasia risk factors that can be the major etiological factor of endometrial carcinoma has especial importance and in other hand help the medical groups for having superb diagnosing and presenting better medical services to high risk groups and significantly reduce side effects and unnecessary medical costs.
منابع مشابه
Evaluation of the Effect of Additive Metformin to Progesterone on Patients with Endometrial Hyperplasia
Background and Objectives: Endometrial hyperplasia (EH) is an abnormal overgrowth of endometrium that may lead to endometrial cancer, especially when accompanied by atypia. The treatment of EH is challenging, and previous studies report conflicting results. Metformin (dimethyl biguanide) is an anti-diabetic and insulin sensitizer agent, which is supposed to have antiproliferative and anticancer...
متن کاملP-99: Relationships between Serum Luteinizing Hormone Level, Endometrial Thickness and Body Mass Index in Polycystic Ovary Syndrome Patients with and without Endometrial Hyperplasia.
Background It is well documented that ulterasonographic endometrial hyperplasia in polycystic ovary syndrome (PCOS) women is strongly related to pathologic endometrial thickness, but there is no consensus on the relation between serum luteinizing hormone (LH) and either of these factors: pathologic endometrial hyperplasia and body mass index (BMI).��� MaterialsAndMethods An observational cross-...
متن کاملP-190: Regression of Endometrial Hyperplasia after Treatment with Drug and Conservative Treatment in Early Abortion: A Case Series Study
Background: The aim of the conservative treatment is the regression of the hyperplastic to normal endometrium. Conservative treatment of endometrial hyperplasia is based on the administration of agents with either antioestrogenic action or direct anti-proliferative effect on the endometrium. Progestagens have been used widely in the treatment of endometrial hyperplasias. Materials and Methods: ...
متن کاملRisk factors for endometrial hyperplasia concomitant endometrial polyps in pre- and post-menopausal women.
PURPOSE To evaluate the risk factors for endometrial hyperplasia concomitant endometrial polyps in pre- and post-menopausal women. MATERIALS AND METHODS A total of 203 patients undergoing endometrial sampling before hysterectomy were evaluated in this retrospective study. Data recorded were age, gravidity, parity, body mass index (BMI: weight(kg)/height(m)2), endometrial thickness (ET), menop...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ذخیره در منابع من قبلا به منابع من ذحیره شده{@ msg_add @}
عنوان ژورنال
دوره 8 شماره 2.5
صفحات 220- 220
تاریخ انتشار 2014-07-01
با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023